Eliminating MRD - FDA approval of blinatumomab for B-ALL in complete remission.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
   Trial
2. Mechanism of Bispecific Antibodies and Clinical Research Advances in Lung Cancer.Current cancer drug targets · 2026
   Review
3. A Comprehensive Exploration of Agents Targeting Tumor Microenvironment: Challenges and Future Perspectives.Journal of immunotherapy and precision oncology · 2024
   Review
4. Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice.Current treatment options in oncology · 2023
   Review
5. Strategies for Manipulating T Cells in Cancer Immunotherapy.Biomolecules & therapeutics · 2022
   Review
6. Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia.Blood and lymphatic cancer : targets and therapy · 2022
   Review
7. Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions.Cancers · 2021
   Review
8. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics.Cellular & molecular immunology · 2020
   Review
9. Evaluation and management of measurable residual disease in acute lymphoblastic leukemia.Therapeutic advances in hematology · 2020
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as